Update on Compliance 

At Regen Therapy we are implementing an update to how peptide and GLP-related programs are referenced and supported across our ecosystem.

Based on recent regulatory guidance and enforcement trends, it has become clear that historical reliance on labels such as “Research Use Only” or “not for human use” does not provide meaningful protection when products or information are marketed, promoted, or referenced in patient-facing clinical contexts. Regulators have been explicit that intent, marketing posture, and downstream use are the primary factors used to assess classification and enforcement risk.

As a result, Regen Therapy is updating its policies to ensure long-term compliance, operational clarity, and durability under increasing federal and state-level scrutiny.

What Is Changing

Effective January 1, 2026, Regen Therapy and its affiliates will no longer support or reference any model that relies on peptides being positioned as “Research Use Only” when the downstream intent involves patient care.

Any peptide- or GLP-related use in patient-facing clinical environments must instead occur within provider-directed clinical programs that are independently governed and overseen by licensed medical professionals.

This policy update is designed to remove ambiguity, align with current regulatory expectations, and help clinics and partners operate with greater confidence.

What This Means in Practice

Under this updated approach:

• Regen Therapy does not sell, prescribe, dispense, or distribute medications

• Regen Therapy does not direct or manage patient care

• Peptides are not positioned as standalone consumer products

• There is no patient self-selection or consumer-facing “menu” of individual compounds

Clinical decisions, including eligibility criteria, contraindications, dosing decisions, monitoring protocols, and informed consent, remain the sole responsibility of licensed providers operating under their own clinical governance and medical oversight.

Regen Therapy’s role is limited to education, infrastructure, and operational enablement, not clinical delivery.

This is a provider-enablement and compliance-forward model, not a retail, e-commerce, or direct-to-consumer prescribing model.

What is no Longer Supported

Beginning January 1, 2026, the following practices are not supported within the Regen Therapy ecosystem:

• Marketing or positioning peptides as “Research Use Only” while enabling or facilitating human use

• Patient-facing purchase flows for peptides without independent provider governance

• Language implying equivalence to FDA-approved drugs or unsupported “generic” claims

• Reliance on disclaimers as a substitute for appropriate clinical oversight or regulatory alignment

How we Are Supporting This Transition

Regen Therapy provides non-clinical infrastructure and resources to support licensed providers as they adapt to evolving regulatory expectations, including:

• Educational resources related to medical directorship models

• Standardized, provider-facing program frameworks and documentation templates

• Compliance-oriented intake, consent, and monitoring workflows

• Operational guidance and staff education support

• Scalable governance frameworks for multi-site and multi-provider organizations

All clinical services and patient care are delivered by independently licensed providers and organizations.

Ready to get compliant? Click Here

Timeline

• Now through December 31, 2025: Transition period for documentation updates, program alignment, and marketing review

• January 1, 2026: Full enforcement of this policy across Regen Therapy partnerships
  
  

Our goal is to help partners stay ahead of regulatory risk while continuing to support high-quality, clinically responsible care.

If you have questions about how this update impacts your organization or would like support during the transition period, our team is available to help.

Thank you for continuing to build responsibly with Regen Therapy.